GlassScriptPhysician profile
Anna Catherine Smith
NPI 1639878580
$4,547.16
in general payments reported to CMS, 2019-2025
25 companies · $1,829 in 2025
The $1,829 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $818 · 2024: $1,900 · 2025: $1,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,034 · Education: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,034.19 |
| Education | $512.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $522.85 | 2023-2025 | |
| Genzyme Corporation | $439.22 | 2023-2025 | |
| Janssen Biotech, INC. | $422.55 | 2023-2025 | Tremfya |
| Dermavant Sciences, INC. | $372.54 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $336.35 | 2023-2025 | Ilumya |
| Arcutis Biotherapeutics, INC. | $316.35 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $316.29 | 2024-2025 | |
| Galderma Laboratories, L.P. | $282.57 | 2024-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $281.33 | 2024-2025 | Sotyktu |
| Leo Pharma INC. | $280.76 | 2023-2025 | Adbry, Anzupgo |
| Organon LLC | $161.88 | 2025 | Vtama |
| Lilly USA, LLC | $141.12 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Biofrontera INC. | $115.91 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $68.30 | 2023-2025 | Dupixent, Libtayo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $66.25 | 2023-2025 | Opzelura |
| Pfizer INC. | $60.02 | 2024-2025 | |
| Ucb, INC. | $55.80 | 2023-2025 | Bimzelx, Cimzia |
| Verrica Pharmaceuticals INC. | $49.33 | 2024-2025 | Ycanth |
| Lnhc, INC | $42.86 | 2025 | Zelsuvmi |
| Sandoz INC. | $38.01 | 2024 | Hyrimoz |
| Almirall LLC | $33.63 | 2025 | Klisyri |
| Amgen INC. | $27.76 | 2025 | Otezla |
| Mayne Pharma Commercial LLC | $23.12 | 2023-2025 | |
| Botanix Sb INC | $20.36 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.